WallStSmart
STOK

Stoke Therapeutics Inc

NASDAQ: STOK · HEALTHCARE · BIOTECHNOLOGY

$32.42
-2.73% today

Updated 2026-04-29

Market cap
$1.92B
P/E ratio
P/S ratio
10.40x
EPS (TTM)
$-0.12
Dividend yield
52W range
$8 – $40
Volume
0.8M

Stoke Therapeutics Inc (STOK) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+43.0%
Last 4 quarters
Revenue YoY growth
-93.8%
Most recent quarter
EPS YoY growth
-438.9%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+3.7%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+28.5%
2025-08-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-11$-0.97-36.0%$38.35$36.48-4.9%
2025-11-04$-0.65-12.1%$26.10$22.82-12.6%
2025-08-12$-0.40+20.0%$13.16$16.91+28.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.71$-0.97-36.0%$1.40M-93.8%
2025-09-30$-0.58$-0.65-12.1%$10.63M+117.2%
2025-06-30$-0.50$-0.40+20.0%$13.82M+186.0%
2025-03-31$-0.09$1.90+2199.4%$158.57M+3661.1%
2024-12-31$-0.53$-0.18+66.1%$22.61M+707.1%
2024-09-30$-0.53$-0.47+11.5%$4.89M+47.9%
2024-06-30$-0.56$-0.46+17.9%$4.83M-294.7%
2024-03-31$-0.61$-0.57+6.6%$4.22M
2023-12-31$-0.63$-0.60+4.8%$2.80M
2023-09-30$-0.63$-0.55+12.7%$3.31M
2023-06-30$-0.64$-0.69-7.8%$-2.48M

Frequently asked questions

Has Stoke Therapeutics Inc beaten earnings estimates?
Stoke Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +43.0% over the last 4 quarters.
How does STOK stock react to earnings?
STOK stock has moved an average of +3.7% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Stoke Therapeutics Inc's revenue growth rate?
Stoke Therapeutics Inc reported year-over-year revenue growth of -93.8% in its most recent quarter, with EPS growing -438.9% year-over-year.